Stone and Laser Therapies Post-Market Study (SALT)
← catalyst calendarNCT06982235 · readout ≤ 924 d
Sponsored by Boston Scientific Corporation (industry) · BSX — their whole pipeline →.
Phase
—
Status
Active, not recruiting
Study type
Observational
Enrollment
238estimated
Sites
5
Country
United States
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2025-06-30 | actual | When the study began enrolling |
| Primary completion | Feb 2029 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | Feb 2029 | estimated | The whole study's end, after follow-up |
| First posted | 2025-05-21 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-08-12 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Conditions
- Benign Prostate Hypertrophy(BPH)
- Renal Calculi
- Ureteral Stones, Kidney Stones
- Calculi, Urinary
- Urinary Tract Procedure
Interventions
- Device: Ureteroscope system
- Device: Laser system
Primary outcome
what the primary-completion date above is the date OFOccurrence of Serious Adverse Events related to BSC study devices
measured From procedure to 12-months after the procedure
Permalink · BSX's whole pipeline · Catalyst calendar · Every registered study · What changed